Increasing struggles in cell therapies manufacturing as production ramps up

Even though there has been an increasing number of cell therapies advancing to late-stage clinical development, several aspects of cell therapy development continue to present considerable challenges for large scale commercialization. It is clear that production of biologics in general carries higher risks than of small molecules pharmaceuticals and this becomes even more evident as production of cell therapies ramps …